Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years

Manno, Mauro; Cammà, Calogero; Schepis, Filippo; Bassi, Fabio; Gelmini, Roberta; Giannini, Francesco; Miselli, Francesca; Grottola, Antonella; Ferretti, Ilva; Vecchi, Chiara; Palma, M. De; Villa, Erica

doi:10.1053/j.gastro.2004.06.021

Cited by 238 publications

(224 citation statements)

References 37 publications

Supporting

Mentioning

201

Contrasting

Unclassified

Order By: Relevance

“…The annual incidence of developing HCC in HBV infected patients at age 70 is 1%. HBV carriers were 100 times more likely to develop HCC than the uninfected patients, but HCC occurs more commonly in patients with established cirrhosis than in noncirrhotic patients (Beasley et al, 1981;Fattovich et al, 1991;Koike et al, 2002;Manno et al, 2004). It has been shown by Beasley at al that the annual incidence of HCC in HBV carriers was 0,5% (Beasley et al, 1981).…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Doğan¹,

Yalçın²,

Koca³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Doğan¹,

Yalçın²,

Koca³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…If this state is reached, prognosis is generally favorable, as there is no active virus, which may persist indefinitely [24]. Some patients will eventually lose HBsAg at a rate of 0.5% to 2.0% per year [25][26][27].…”

Section: Birth 90%mentioning

confidence: 99%

Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada

Huynh¹,

Minuk

Uhanova

et al. 2017

Vaccine

View full text Add to dashboard Cite

show abstract

“…The incidence of spontaneous HBsAg seroclearance varies considerably in different series with an annual incidence of 1-2%, and does not differ much between Caucasian and Asian carriers (28)(29)(30)(31). A long-term (415 years) inactive carrier state is usually required to achieve subsequent HBsAg seroclearance.…”

Section: Hbsag: Clinical Relevancementioning

confidence: 99%

Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B

Moucari

Marcellin

2011

Liver International

View full text Add to dashboard Cite

HBsAg is a very important clinical test that might not only indicate active hepatitis B virus (HBV) infection but might also be used to predict clinical and treatment outcome. Clearance of HBsAg in patients with chronic HBV infection is associated with a much better clinical outcome, although surveillance for early detection of hepatocellular carcinoma (HCC) should continue. HBV DNA quantification is currently used for selecting candidates for therapy, monitoring response to therapy and detecting the emergence of drug resistance. Assays for HBsAg quantification are less expensive than HBV DNA and fully automated with a high throughput capacity. HBsAg titering may be a useful tool to manage patients with chronic HBV, to more clearly define which patients may, and more importantly, may not, benefit from treatment. Baseline and on-treatment HBsAg quantification may help to refine future treatment algorithms for both immune-modulator therapy and nucleos(t)ide analogues. Both HBV markers provide complementary information on the status of HBV infection. However, the relevance of serum HBsAg levels and its use as a reliable replacement for both covalently closed circular DNA and HBV DNA remain unclear.

show abstract

Natural history of chronic HBV carriers in northern Italy: Morbidity and mortality after 30 years

Cited by 238 publications

References 37 publications

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Clinicopathological Characteristics of Hepatocellular Carcinoma in Turkey

Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada

Quantification of hepatitis B surface antigen: a new concept for the management of chronic hepatitis B

Contact Info

Product

Resources

About